Nippon ChemipharNIPPON CHEMIPHAR CO., LTD.4539東証スタンダード医薬品FY ending Mar 2026, consolidated, J-GAAP
Operating profit was close to zero, a slight profit per ¥100 of sales. Revenue changed +1.6% from the prior year, operating profit -70.5%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 2.2% | 0.66× | 1.4% | 3.10× | 4.4% |
| 2023 | 1.1% | 0.64× | 0.7% | 3.06× | 2.1% |
| 2024 | — | —× | -0.4% | —× | — |
| 2025 | 0.9% | 0.66× | 0.6% | 3.14× | 1.9% |
| 2026 | 0.6% | 0.66× | 0.4% | 3.14× | 1.2% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 32,506 | 31,559 | 30,748 | 32,570 | 33,090 |
| Cost of revenue | 23,432 | 23,374 | 23,010 | 23,824 | 24,693 |
| Gross profit | 9,073 | 8,184 | 7,737 | 8,746 | 8,397 |
| SG&A | 8,248 | 8,425 | 8,232 | 8,139 | 8,217 |
| Operating income | 825 | -241 | -494 | 606 | 179 |
| Pretax income | 976 | 480 | -202 | 253 | 221 |
| Income tax | 275 | 141 | -21 | -41 | 23 |
| Net income attributable to owners | 700 | 339 | -180 | 294 | 198 |
| Operating margin | 2.5% | -0.8% | -1.6% | 1.9% | 0.5% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥11.6B | ¥10.5B | ¥9.2B | ¥7.02B | ¥5.34B |
| Total assets | ¥49.5B | ¥48.6B | ¥49.5B | ¥49.9B | ¥50B |
| Net assets | ¥18.5B | ¥18.5B | ¥18.5B | ¥19.2B | ¥19.5B |
| Share capital | ¥4.3B | ¥4.3B | ¥4.3B | ¥4.3B | ¥4.3B |
| Property, plant and equipment | ¥11.8B | ¥11.5B | ¥13.2B | ¥14.7B | ¥14.3B |
| Intangible assets excluding goodwill | ¥884M | ¥569M | ¥281M | ¥494M | ¥499M |
| Investment securities | ¥1.81B | ¥1.39B | ¥2.07B | ¥1.92B | ¥2.07B |
| Current assets | ¥33.5B | ¥33.4B | ¥31.8B | ¥30.1B | ¥29.9B |
| Current liabilities | ¥16.8B | ¥14.8B | ¥13.8B | ¥12.3B | ¥12.7B |
| Trade payables | ¥2.15B | ¥2.54B | ¥2.02B | ¥2.37B | ¥1.87B |
| Short-term borrowings | ¥400M | ¥392M | ¥568M | ¥230M | ¥174M |
| Long-term borrowings | ¥11.4B | ¥11.9B | ¥13.3B | ¥13.3B | ¥12.3B |
| Total liabilities | ¥31B | ¥30B | ¥31.1B | ¥30.7B | ¥30.5B |
| Equity attributable to owners of parent | ¥15.9B | ¥16.1B | ¥15.7B | ¥15.9B | ¥16B |
| Retained earnings | ¥13.5B | ¥13.6B | ¥13.3B | ¥13.4B | ¥13.5B |
| Treasury stock | -¥3.11B | -¥3.11B | -¥3.11B | -¥3.11B | -¥3.08B |
EDINET (FSA Japan)
有価証券報告書－第94期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第93期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第92期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第91期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第90期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第89期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 50 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.